The ARV Therapies and Therapeutic Strategies program is a comprehensive, independent review of the 28th Conference on Retroviruses and Opportunistic Infections (CROI 2021). This program consists of two components: (1) From Conference to Clinic: Reviewing and Applying Data from CROI 2021: a case-based webcast featuring expert faculty reviewing key presentations with a focus on clinical management and treatment; (2) CROI 2021 e-Newsletter: a brief on-line summary of the most essential data presented at the conference.
The CME Internet Symposium: From Conference to Clinic: Reviewing and Applying Data from CROI 2021 will feature a panel of HIV experts reviewing key presentations on antiretroviral therapy presented at CROI 2021. The review will include several clinical cases focusing on HIV therapeutic options and developments, including: current treatment and management strategies; algorithms and recommendations; therapies in development; epidemiology, diagnosis and clinical management of specific patient populations. This activity will enable participating health care providers caring for HIV-infected patients to become aware of and understand the data presented at this important conference and appropriately utilize those data to improve patient care. All on-line components of the program can be accessed at www.viraled.com.
This program is jointly provided by the Postgraduate Institute for Medicine and ViralEd. It is not a session created by or presented at CROI 2021 and it is not sanctioned by the organizers of CROI 2021.
This activity has been designed to meet the educational needs of physicians, physician assistants, advanced practice nurses and other health care professionals involved in the care of patients with HIV infection.
After completing this activity, the participant should be better able to:
Release Date: March 19, 2021
Expiration Date: March 19, 2022
Estimated time to complete each Module: 30-45 minutes
Media: Web
José Arribas, MD
Senior Attending Physician, HIV Unit
Hospital de La Paz
Madrid, Spain
Graeme Moyle, MD, MB, BS
Associate Director of HIV Research
Chelsea & Westminster Hospital
London, United Kingdom
Jürgen Rockstroh, MD
Professor of Medicine
Department of Medicine
University Hospital
Bonn, Germany
Paul Sax, MD
Clinical Director
Division of Infectious Diseases
Brigham and Women's Hospital
Professor of Medicine
Harvard Medical School
Boston, Massachusetts
Renslow Sherer, MD
Professor of Medicine
Section of Infectious Diseases and Global Health
University of Chicago
Chicago, Illinois
 |
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and ViralEd, Inc. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. |
Module 1 (COVID-19 and COIVID-19/HIV):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 2 (Hepatitis and PrEP):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 3 (HIV Treatment Experienced Patients):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Module 4 (Comorbidities and Adverse Events):
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Postgraduate Institute for Medicine (PIM) requires faculty, planners and others in control of educational content to disclose all thier financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineleigible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the content of this CME activity:
Jose Arribas, MD
Graeme Moyle, MD
Jürgen Rockstroh, MD
Paul Sax, MD
Renslow Sherer, MD
1) Go to http://www.cmeuniversity.com/
2) Login or Create a New Account (will take less than 1 minute)
a) If you receive a message when creating a new account that "the
email you entered is already in use", please click the Forgot my
Username or Password link to have your Username and Password sent to you
via email
b) After logging in, you may be asked to verify/update your information; after doing so, click Save at the bottom of the page
3) Type in 15990 at the top of the page, "Find Post-Test/Evaluation by Course", and click enter
4) Click on the activity title when it appears
5) Choose the type of credit you desire
6) (If applicable) Complete the Post-test with a passing score of 75% or better
7) Complete the online Evaluation
8) Receive an immediate CE Certificate to download and/or print for your files
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This activity is supported by an independent educational grant from Janssen Therapeutics, Division of Janssen Products LP.
This coverage is not sanctioned by the conference organizers and is not an official part of the conference proceedings.
*Greenwich Mean Time
